ArticleMolecular biology reports2025
Downregulation of miRNA-133a and miRNA-452 associated with upregulation of CLNK and LEF1 genes in chronic lymphocytic leukemia: in vitro and in silico insights.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic lymphocytic leukemia (CLL), a common B-cell malignancy, exhibits diverse clinical outcomes influenced by microRNA (miRNA) dysregulation. This study investigates the expression and regulatory roles of miRNA-133a and miRNA-452 in CLL. METHODS AND
resultsPeripheral blood samples from 63 CLL patients and 50 age-matched healthy controls were analyzed using quantitative real-time PCR (qRT-PCR), revealing significant downregulation of miRNA-133a and miRNA-452 in patients compared to controls (p < 0.001). Concurrently, predicted target genes CLNK and LEF1 were upregulated (p < 0.001). Age-stratified analysis showed lower miRNA-133a and miRNA-452 expression in patients aged ≤ 55 years versus > 55 years (p = 0.034 and p = 0.033, respectively). In silico analyses using miRTarBase, TargetScan, and GEO2R (GSE22529) confirmed regulatory interactions between miRNA-133a and CLNK, and miRNA-452 and LEF1, with CpG island hypermethylation (GSE151010) potentially contributing to miRNA downregulation. Competing endogenous RNA (ceRNA) networks involving MALAT1, CDR1as, NEAT1, and PTEN were identified, suggesting miRNA sequestration.
conclusionsThese findings indicate that miRNA-133a and miRNA-452 downregulation, coupled with CLNK and LEF1 upregulation, may drive CLL pathogenesis, with age-related differences highlighting their potential as diagnostic biomarkers. Further validation in larger cohorts and functional studies are warranted to elucidate their mechanistic roles.
Indexed as
Identifiers
41191156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.